Metraipolis › archive › dc_fdc5386e4c76
Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42499715
- DOI
- 10.1002/jpr3.70212
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T11:18:20.359Z
- SHA-256 of the archived text
5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1- Stable URL of this page
https://metraipolis.com/documento/dc_fdc5386e4c76
How to cite
Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715 — Europe PMC (en), https://europepmc.org/article/MED/42499715 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fdc5386e4c76 (Metraipolis archive dc_fdc5386e4c76, sha256 5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1)
BibTeX
@misc{dcfdc5386e4c76,
title = {Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease — Europe PMC PMID:42499715},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42499715},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fdc5386e4c76; sha256 5233248d4d5a9529a18b26f8114ec5deee2135213200393271cb5e4f7bc9e6c1},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42499715. Agents can read the archived copy with the MCP tool read_document.